S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
NASDAQ:ATHE

Alterity Therapeutics - ATHE Stock Forecast, Price & News

$3.94
+0.07 (+1.81%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.87
$4.00
50-Day Range
$2.95
$4.29
52-Week Range
$2.90
$10.50
Volume
14,498 shs
Average Volume
29,900 shs
Market Capitalization
$15.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00

Alterity Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
534.5% Upside
$25.00 Price Target
Short Interest
Healthy
0.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.20mentions of Alterity Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

540th out of 1,030 stocks

Pharmaceutical Preparations Industry

270th out of 502 stocks

ATHE stock logo

About Alterity Therapeutics (NASDAQ:ATHE) Stock

Alterity Therapeutics Ltd. engages in the research and development into Parkinsonian and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Receive ATHE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alterity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATHE Stock News Headlines

Appendix 4C - Q2 FY23 Quarterly Cash Flow Report
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Appendix 4C - Q1 FY23 Quarterly Cash Flow Report
See More Headlines
Receive ATHE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alterity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATHE Company Calendar

Today
2/02/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATHE
Employees
11
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.00
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+534.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.37 million
Book Value
$6.41 per share

Miscellaneous

Free Float
2,455,000
Market Cap
$15.80 million
Optionable
Not Optionable
Beta
1.21

Key Executives

  • Geoffrey Paul Kempler
    Chairman
  • David A. Stamler
    Chief Executive Officer
  • Kathryn J. E. Andrews
    Chief Financial Officer
  • Phillip Allen Hains
    Secretary













ATHE Stock - Frequently Asked Questions

Should I buy or sell Alterity Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alterity Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ATHE shares.
View ATHE analyst ratings
or view top-rated stocks.

What is Alterity Therapeutics' stock price forecast for 2023?

2 analysts have issued 1-year price targets for Alterity Therapeutics' shares. Their ATHE share price forecasts range from $20.00 to $30.00. On average, they anticipate the company's share price to reach $25.00 in the next twelve months. This suggests a possible upside of 534.5% from the stock's current price.
View analysts price targets for ATHE
or view top-rated stocks among Wall Street analysts.

How have ATHE shares performed in 2023?

Alterity Therapeutics' stock was trading at $3.4820 at the beginning of 2023. Since then, ATHE stock has increased by 13.2% and is now trading at $3.94.
View the best growth stocks for 2023 here
.

Are investors shorting Alterity Therapeutics?

Alterity Therapeutics saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 13,100 shares, an increase of 10.1% from the December 31st total of 11,900 shares. Based on an average daily trading volume, of 12,500 shares, the days-to-cover ratio is presently 1.0 days. Approximately 0.3% of the company's stock are short sold.
View Alterity Therapeutics' Short Interest
.

When did Alterity Therapeutics' stock split?

Alterity Therapeutics's stock reverse split before market open on Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Alterity Therapeutics own?
What is Alterity Therapeutics' stock symbol?

Alterity Therapeutics trades on the NASDAQ under the ticker symbol "ATHE."

How do I buy shares of Alterity Therapeutics?

Shares of ATHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alterity Therapeutics' stock price today?

One share of ATHE stock can currently be purchased for approximately $3.94.

How much money does Alterity Therapeutics make?

Alterity Therapeutics (NASDAQ:ATHE) has a market capitalization of $15.80 million and generates $3.37 million in revenue each year.

How can I contact Alterity Therapeutics?

Alterity Therapeutics' mailing address is LEVEL 3 460 BOURKE STREET, MELBOURNE C3, VIC 3000. The official website for the company is www.alteritytherapeutics.com. The company can be reached via phone at (139) 349-4906, via email at alterity@we-buchan.com, or via fax at 61-3-9348-0377.

This page (NASDAQ:ATHE) was last updated on 2/3/2023 by MarketBeat.com Staff